ROXI-CAT-INCT07410117
REGN7508 in Adult Participants for Prevention of Cancer-Associated Thrombosis
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 10 versions: 10 with changes below. See every version on ClinicalTrials.gov ↗
- Minor Trial sites expanded: 23 → 28 locations
- Minor Trial sites expanded: 20 → 23 locations
- Minor Study sites revised (20)
- Notable Eligibility criteria expanded, about 8 words
- Trial sites expanded: 14 → 20 locations
- Minor Study sites: 13 to 14v6
- Minor Study sites: 12 to 13v5
- Notable Primary endpoint(s) modified
- Eligibility criteria shortened, about 6 words
- Enrollment increased: 860 → 1120 participants
- Secondary endpoints: 8 to 16
- Minor Trial sites expanded: 5 → 12 locationsv3
Notable Trial status: Not Yet Recruiting to Recruitingv2 Show 4 more changesShow less
- Primary completion date: Jul 21, 2029 to Jan 23, 2030
- Study sites: 0 to 5
- Study completion date: Nov 1, 2029 to May 6, 2030
- Start date changed from estimate of Feb 16, 2026 to Mar 9, 2026
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Time-to-first event of centrally adjudicated VTE (DVT, PE) or ATE, or thromboembolism- or ATE-related death
Timeframe: Through 6 months
Time-to-first event of centrally adjudicated International Society of Thrombosis and Hemostasis (ISTH) major bleeding or Clinically Relevant Non-Major (CRNM) bleeding
Timeframe: Through 6 months
Secondary (16)
Time-to-first event of the centrally adjudicated symptomatic or incidental VTE (DVT, PE) or ATE and thromboembolism- or ATE-related death
Time-to-first event of symptomatic VTE
Time-to-first event of symptomatic DVT
Time-to-first event of symptomatic non-fatal PE
Time-to-first event of thromboembolism-related death
Show 11 moreShow less
Time-to-first event of incidental VTE
Time-to-first event of incidental upper extremity or incidental proximal lower extremity DVT
Time-to-first event of incidental non-fatal PE (in a segmental or larger pulmonary artery)
Time-to-first event of asymptomatic VTE (Asymptomatic DVT detected by lower extremities ultrasound)
Time-to-first event of ATE
Time-to-first event of ATE-related death
Time-to-first event of centrally adjudicated VTE (DVT, PE), or thromboembolism-related death
Occurrence of Treatment-Emergent Adverse Events (TEAEs)
Severity of TEAEs
Occurrence of Anti-Drug Antibody (ADA) to REGN7508
Magnitude of ADA to REGN7508
Arms and interventions
REGN7508Experimental
PlaceboPlacebo comparator
Drugs: REGN7508, Placebo
Sites
28 sites in 3 countries
Japan 13, Georgia 10, United States 5